Profiling immune responses in paediatric and high-risk populations to the COVID-19 virus (PROPHECY)
COVID-19 vaccines protect against severe disease. But people with underlying health conditions remain at risk of infection and associated complications. This study will evaluate immune responses after infection or vaccination in healthy and vulnerable people. The findings will inform future clinical care for COVID-19 and targeted approaches to improve vaccine responses in vulnerable patient groups.
We're evaluating antibody and cellular immune responses after infection or vaccination in healthy and vulnerable people to evaluate their protection against future variants.
We'll comprehensively profile the immune responses to the COVID-19 virus (SARS-CoV-2) using clinical samples collected from 11 vulnerable and immunocompromised cohorts (adults and paediatrics) and healthy individuals who have been vaccinated. Serological antibody responses and cellular responses T-cells and B-cell will be measured.
Generating knowledge and evidence to improve vaccine schedules, future booster strategies and improved access to clinical care for vulnerable populations. In addition, our findings will inform future clinical trials to enhance vaccine responses in immunocompromised people.
Timeline
2022–2026.
Publications
Fourth dose bivalent COVID-19 vaccines outperform monovalent boosters in eliciting cross-reactive memory B cells to Omicron subvariants
Journal of Infection
Holly A. Fryer et al
Serological responses and clinical outcomes following a three‐dose primary COVID‐19 vaccine schedule in kidney transplant recipients and people on dialysis
Clinical & Translational Immunology
Dhakshayini Tharmaraj et al
COVID-19 Adenoviral Vector Vaccination Elicits a Robust Memory B Cell Response with the Capacity to Recognize Omicron BA.2 and BA.5 Variants
Journal of Clinical Immunology
Holly A. Fryer et al
Partners
Funding partners
Medical Research Future Fund (MRFF): 2021 COVID-19 Treatment Access and Public Health Activities.
Collaborators
- Alfred Health
- Monash Health
- Monash University
- Murdoch Children’s Research Institute
Consumer health partners
- Spleen Australia
- AusPIPS
- National Association of people with HIV Australia
- Musculoskeletal (MSK) Australia
- Crohn’s and Colitis Australia
- Safer Care Victoria
Project contacts
Main contacts
Professor Heidi Drummer
Scientific Director for Research Translation; Scientific Director, Burnet Diagnostics Initiative; Principal Investigator, Burnet Vaccine Initiative; Co-Head, Viral Entry and Vaccines Group
Project team
Professor Heidi Drummer
Scientific Director for Research Translation; Scientific Director, Burnet Diagnostics Initiative; Principal Investigator, Burnet Vaccine Initiative; Co-Head, Viral Entry and Vaccines Group
Dr Gabriela Khoury
Theme Leader, Antiviral Immunity
Irene Boo
Research Assistant, Drummer/Poumbourios Laboratory
Dr Dilini Rathnayake
Research Officer
Dr James McMahon
Adjunct Senior Research Fellow
Alfred Hospital; Monash University
Professor Menno van Zelm
Professor of Molecular Immunology
Monash University; Erasmus University Medical Center, Netherlands
Dr Ian Woolley
Infectious Diseases Physician; Director, Monash Infectious Diseases
Monash Infectious Diseases, Monash University
Associate Professor Alberta Hoi
Senior Consultant
Monash Health
Professor Anne Holland
Professor of Physiotherapy
Alfred Health; Monash University
Professor David Curtis
Clinical Haematologist
Alfred Health; Monash University
Dr Miles Sparrow
Adjunct Clinical Associate Professor
Alfred Health; Monash University
Associate Professor James Trauer
Head of Epidemiological Modelling
School of Public Health and Preventive Medicine, Monash University
Dr Benjamin Rogers
Adjunct Clinical Associate Professor
Monash Health; Monash University
Associate Professor William Mulley
Nephrologist
Monash Health
Dr Samar Ojaimi
Infectious Diseases Physician
Monash Health
Dr Ed Giles
Research Fellow
Monash University